Recent Updates
Recently added Catalysts
RGEN Positive Sentiment

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

Key Takeaway: Repligen Corporation will participate in the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. CEO Olivier Loeillot and CFO Jason Garland will engage in an analyst-led discussion. A live webcast will be available for those unable to attend in person, highlighting the company's focus on bioprocessing technologies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Repligen Corporation is participating in a major healthcare conference.
  • The event features key executives discussing company strategies.
  • Live webcasts enhance accessibility for investors and stakeholders.

Full Press Release Details

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9 th at 1:30 p.m. ET.
A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact: Jacob Johnson VP, Investor Relations 781-419-0204 investors@repligen.com

Frequently Asked Questions

When is Repligen's presentation at the conference?

Repligen's presentation is scheduled for September 9, 2026, at 1:30 p.m. ET.

Who will represent Repligen at the conference?

Olivier Loeillot, CEO, and Jason Garland, CFO, will represent Repligen.

How can I access the conference presentation?

The presentation will be available via a live webcast on Repligen's Investor Relations website.

What is Repligen Corporation focused on?

Repligen focuses on developing bioprocessing technologies for biological drug manufacturing.

Last updated: Aug 26, 2026